Thank you for submitting your manuscript for consideration by the EMBO Journal. It has now been seen by three referees whose comments are enclosed. As you will see, all three reviewers express interest in your study, but all have significant concerns that would need to be addressed by a major revision of your work before we could consider publication.
Most notably, both referees 2 and 3 comment on the quality and extent of the cell biological data presented. I would particularly draw your attention to referee 3's first major point -namely that analysis of the effects of the ZO-1 and MRCKb interaction mutants (which you do already have) would be critical to reveal the importance of this interaction for migration. Both these referees also comment on the need for better immunofluorescence data and the need for rigorous quantification of the observed effects. The second major area of concern -as highlighted by referee 1 -regards the rationale behind the use of the GRINL1A peptide as a substitute for MRCKβ for the structural work. Both we and the referee do recognise that you were unable to conduct this experiment with the MRCKb peptide, but some additional explanation and ideally data to support your hypothesis that the GRINL1A complex is relevant for the ZO-1/MRCKβ interaction would be important here. Finally, both referees 1 and 2 comment on the readability of the text: I would encourage you either to have your manuscript read by a native English speaker, or to have it professionally copy-edited.
In the light of the referees' positive recommendations, I would therefore like to invite you to submit a revised version of the manuscript, addressing the comments of all three reviewers (particularly but not only those highlighted above). I should add that it is EMBO Journal policy to allow only a single round of revision. Acceptance of your manuscript will thus depend on the completeness of your responses included in the next, final version of the manuscript. When preparing your letter of response to the referees' comments, please bear in mind that this will form part of the Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process initiative, please visit our website: http://www.nature.com/emboj/about/process.html
We generally allow three months as a standard revision time, and as a matter of policy, we do not consider any competing manuscripts published during this period as negatively impacting on the conceptual advance presented by your study. However, we request that you contact the editor as soon as possible upon publication of any related work, to discuss how to proceed. Should you foresee a problem in meeting this three-month deadline, please let us know in advance and we may be able to grant an extension.
Thank you for the opportunity to consider your work for publication. I look forward to your revision.
Yours sincerely, Editor
The EMBO Journal REFEREE REVIEWS Referee #1 (Remarks to the Author):
The manuscript by Huo et al describes a detailed study of the interaction of the ZO-1 protein with MRCKβ at the leading edge during migrations. The study rests on their identification of the interaction of the two proteins using the yeast two-hybrid assay. The manuscript relies strongly on structural data. ZO-1 is shown to bind to MRCKβ kinase in a Cdc42-dependent fashion, and the interaction -not observed in confluent COS-7 cells, but only in scratch-wounded cells -is mediated by the ZU5 domain. The authors describe a solution (NMR) structure for the isolated ZU5 domain in its mutated form (M1699A; C1700A) which does not interact with MRCKβ, because the wild-type protein showed aggregation which made it impossible to record high quality NMR spectra. Further, the authors pursued the question of the nature of the interaction of the ZU5 domain with its target. Because they were unable to obtain structural data for the complex containing the target oligopeptide from MRCKβ, they characterized the complex with an oligopeptide derived from another protein -GRINL1A. This other target was also observed in Y2H screens, although the authors suggest it may not be physiological. Finally, the authors suggest based on several experiments that the interactions between ZO-1 and MRCKβ is Cdc42 dependent and that, in the absence of Cdc42 in its active form, MRCKβ exists in a closed conformation stabilized by the PH-CH tandem. This is an interesting and fairly well written story, which adds to our understanding of the biology of the ZO-1 protein. However, there are important loose ends in this work that should be addressed before the manuscript is accepted for publication. 1. The NMR structure described in the paper is that of a mutant M1699A; C1700A which does not bind MRCKβ. The rationale is understandable, but it is unclear how the mutation was identified. Further, the description of the complex structure (p. 11-13) does not clearly explain why the mutant is not biologically active. 2. The authors declare on p. 11 that they failed to characterize the biologically relevant complex due to the poor behavior of samples. This is why they chose the GRINL1A oligopeptide, even though this oligopeptide may be derived from a non-biological interaction. I appreciate the authors' dilemma here, but the fact that things did not work out is no excuse. As far as I can tell from Fig 5 the peptide used has only one residue in common with the physiological sequence. I am not really sure if the structure of the complex is really representative of the biological interaction -it is really a long shot. 3. The Kd for the interaction with GRLINL1A is given (µM range), but it is neither explained how this was measured, not is the equivalent constant for the biological oligopeptide target provided. 4. The autoinhibitory mechanism of MRCKβ described in the paper and depicted in Fig 6E is largely based on speculation. The authors should really decide what the focus of their study is. If they want to address the complete story, more work needs to be done to substantiate the autoinhibitory mechanism of MRCKβ. If ZO-1 is the focus, then it is very important to obtain a representative crystal structure.
There are numerous problems with style and language throughout the manuscript, but I think that in the context of the broader problems, they can be addressed when/if a revised version of this manuscript is submitted.
Referee #2 (Remarks to the Author):
In their manuscript, Huo and co-workers describe the formation of a Cdc42-MRCKbeta-ZO-1 complex at the leading edge of migrating cells and show that this complex is involved in regulation on cell migration. They describe in molecular detail the structural basis/requirements of ZO-1-ZU5-MRCKbeta binding and the role for active Cdc42 in the conformational changes of MRCKbeta. This is a very interesting study which provides mechanistic insight into the recently described intriguing localization of ZO-1 in the lamellipodia. The structural and biochemical data of this study are very high-quality and make a strong case in defining the molecular details of the formation of the ZO1-MRCKbeta-Cdc42 complex. However, the cell biological and imaging data are not on a sufficient level for publication in EMBO Journal and they need to be revised before the paper is acceptable for publication. Furthermore, the paper would benefit from re-writing (some of the experiments are not sufficiently described) and professional revision of the English language.
Major points: -The quality of most immunofluorescence (IF) is poor (especially figure 2 and 4) to draw any major conclusions on general localization of proteins. In most of the images cells look morphologically very different and might represent the somewhat heterogeneous nature of COS-7 cells. Quantification of changes in localization upon treatments/different constructs should be done from tens of cells (like for example using free Image J software and Pearson's correlation co-efficient).
-The paper would benefit if the main findings (regarding localization and migration) could be reproduced also in a human cancer cell line.
-In all of the co-IPs it is necessary to show blots for both of the proteins ( Figure 1E2 and 4D there is no ZO-1 blot shown). Figure 2B6 the knock-down of MRCKbeta does not influence leading edge localisation of ZO-1. However, in the image this is not the case.
-Is proliferation altered in any KD conditions which could affect cell migration e.g. in fig 7? -In Figure 7 it seems that in D and G also non-GFP cells are actively migrating into the wound even though one would assume that the rescue-construct would support migration only in the transfected cells. Why is this?
-Phorbol esters are shown to bind MRCKa/b (Choi et al. 2008 ). Could they by-pass the requirement for active Cdc42? -In figure 6D the authors state that active Cdc42 supports MRCKbeta recruitment to the leading edge, however in the image MRCKbeta is equally localizing to the lamellipodia in the transfected and the non-transfected cell shown in the bottom middle panel.
Referee #3 (Remarks to the Author):
The contribution of this work is the identification of a novel protein-protein interaction, a structural analysis of the interaction, and an attempt at understanding the cellular role of the interaction. How cell migration is regulated is a fundamental problem in Biology and elucidating the role of a protein historically thought to regulate cell junctions in this process is a useful advance. I enjoyed reading the paper and found the figures to be clear and aesthetically pleasing. I highly recommend publication if the conclusions regarding the in vivo role of the interaction between ZO-1 and MRCKβ can be supported by the data. In its current form, the paper has two fundamental flaws in this regard:
• The authors conclude that the "ZO-1/MRCKβ complex is required for cell migrations". They base this conclusion on phenotypes in a wound-healing assay where either ZO-1 or MRCKβ is knocked down by RNAi. However, the correct conclusion from this experiment is that both proteins are required for wound-healing, not that the interaction between them is required. Additional experimentation should be performed to properly test the cellular role of this interaction.
• The authors conclude that "ZO-1 plays an active role in regulating cell migration by physically anchoring Cdc42-activated MRCKβ at the leading edges of migrating cells." Once again I believe they have overstated their conclusion. There are several alternative models consistent with their data that do not involve physical anchoring. For example, ZO-1 could be upstream of Cdc42 (which is lipid modified and could very well be sufficient for physical anchoring), ZO-1 could increase the affinity of MRCKβ for Cdc42 (undoubtedly it does),... Thus, the data presented in the paper does not adequately discriminate between possible models for the role of ZO-1 in MRCKβ regulation. Figure 2A6 is not meaningful without knowing how a "cell periphery that contains a fluorescent signal" is defined. What is the threshold for this scoring mechanism? Ideally a relative measurement would be used, such as cortical/cytoplasmic. Point-by-point responses to the comments and suggestions raised by the reviewers Reviewer #1: 1. The NMR structure described in the paper is that of a mutant M1699A/C1700A which does not bind MRCKβ. The rationale is understandable, but it is unclear how the mutation was identified. Further, the description of the complex structure (p. 11-13) does not clearly explain why the mutant is not biologically active.
Minor point • The quantification in
In the original manuscript, we did not go into details in describing our painstaking experience in identifying the M1699A/C1700A mutant for the structural-based studies. It took one of my Ph.D. students more than 4 years to find the mutant. In the process, we have made >50 point and deletion mutations of the domain based on extensive amino acid sequence analysis and structural predictions. Many of the mutants were expressed as inclusion bodies. We purified >30
15 N-labeled ZU5 mutants along the journey. The sample conditions of each mutant were probed by 1 H-15 N HSQC-based NMR experiment. With this iterated trials, we eventually found that the mutant with Met1699 and Cys1670 substituted with Ala residues displayed excellent HSQC spectrum even at very high concentrations (Supplementary figure 3) . We included a very brief description of the mutant identification in the revised manuscript.
As suggested by the reviewer, we have expanded a bit in explaining why the MC/AA mutant is not biologically active (Page 12, Supplementary figures 3D and 8). Our structural and biochemical analysis indicates that the MC/AA mutation keeps ZO-1 ZU5 in the closed, inactive conformation. This mutation-induced stabilization of the closed conformation is due to the fold-back of β5 to form an antiparallel β-sheet with β6, thus preventing ZO-1 ZU5's target from pairing to both β5 and β6 (Supplementary figure 8) . We thank the reviewer for understanding the dilemma that we faced in handling the ZO-1 ZU5/MRCKβ complex, and we fully agree with the reviewer that the ideal data would be the complex structure of the ZO-1 ZU5/MRCKβ complex. We tried very hard but with no success. In order to gain information about the target binding properties of ZO-1 ZU5, we used GRINL1A as a model target with understanding of potential caveat of our choice. After the determination of the ZO-1 ZU5/GRINL1A complex structure, we found that the GRINL1A peptide binds to ZO-1 ZU5 with a β-hairpin conformation to complete the partial ZU5 fold into a complete one ( Figure 5 and Supplementary figure 7) . The sequence alignment analysis showed that the corresponding fragment from MRCKβ and the GRINL1A peptide can be aligned well with each other. Importantly, in this alignment the key hydrophobic residues (highlighted with orange dots) responsible for the hydrophobic core packing of the ZU5 β-barrel are in the proper registers of the β-sheet ( Figure 5B ). We further showed that mutations of these conserved hydrophobic residues abolished the interaction between ZO-1 ZU5 and MRCKβ ( Figure 5D ).
Nonetheless, we concur with the reviewer's concern that the evidences available to us are still not sufficiently strong to draw the conclusion. During the revision, we have performed an additional set of experiments (Supplementary figure 5 of the revised manuscript). We reasoned that the same set of ZO-1 ZU5 mutants defective in binding to MRCKβ would also be defective in interacting with GRINL1A, if the two targets share a similar binding mode to the ZO-1 ZU5 domain. Indeed, either the removal of the last β-strand or the deletion of F1748 eliminated GRINL1A's binding to ZO-1 ZU5 (Supplementary figure 5A) . Additionally, we showed that the full-length GRINL1A can target the wild type ZO-1 ZU5 to the junctional membranes in MDCK cells as GRINL1A is a transmembrane protein. In contrast, neither ZU5(ΔCT) nor ZU5(ΔF1748) could be targeted to membranes by GRINL1A (Supplementary figure 5B) . The data presented in Supplementary figure 5 parallel well with the data shown in Figure 4 , further supporting that MRCKβ and GRINL1A are likely to bind to ZO-1 ZU5 using a similar mechanism. However, as we have emphasized in our manuscript, the final interaction mode between MRCKβ and ZO-1 ZU5 remains to be experimentally proven in the future.
The Kd for the interaction with GRLINL1A is given (~20 µM range), but it is neither explained how this was measured, not is the equivalent constant for the biological oligopeptide target provided.
The GRINL1A peptide was commercially synthesized and conjugated with fluorescein 5-isothiocyanate (FITC) via its N-terminal amino group, and the fluorescence titration was performed with an increasing amount of ZO-1 ZU5 and a constant amount of the fluorescence-labeled peptide. We have included this information in the legend of Supplementary figure 5 in the revised manuscript.
Since we were not able to obtain isolated MRCKβ ZBD, we could not obtain a quantitative binding affinity between MRCKβ ZBD and ZO-1 ZU5. However, we were able to obtain stable ZO-1 ZU5/MRCKβ ZBD complex by co-expressing the two proteins together in bacterial cells (Supplementary figure 9) . The stable co-elution of ZO-1 ZU5 and MRCKβ ZBD in two consecutive chromatographic steps provides a good indication of their stable association. At the current stage, we have to concede that we are able to measure the quantitative binding affinity of the ZO-1 ZU5/MRCKβ ZBD complex.
The autoinhibitory mechanism of MRCKβ described in the paper and depicted in Fig 6E is largely based on speculation. The authors should really decide what the focus of their study is. If they want to address the complete story, more work needs to be done to substantiate the autoinhibitory mechanism of MRCKβ. If ZO-1 is the focus, then it is very important to obtain a representative crystal structure.
The model drawn in Figure 6E is based on the data presented in the manuscript. We observed that the PH-CH-CRIB domain tandem prevents the binding of ZO-1 to MRCKβ. Biochemically, the addition of Cdc42 to the ZO-1 and MRCKβ mixture facilitate the formation of the ZO-1/MRCKβ complex, presumably by Cdc42-mediated release of the closed conformation of MRCKβ ( Figure 6A and 6B). We further show in the revised manuscript that a direct interaction between the PH-CH-CRIB domains and the CC3-C1 domains of MRCKβ can be detected in a Y2H-based assay, further supporting the C-terminal fold-back, closed conformation of MRCKβ (Supplementary figure 10A) . Since the MRCKβ mutant lacking the CRIB domain no longer showed a Cdc42-depedent ZO-1 ZU5 binding ( Figure 6B ), we believe Cdc42 facilitates the ZO-1/MRCKβ by directly binding to the CRIB domain of the enzyme. However, we agree with reviewer that the detailed atomic level of auto-inhibition mechanism of MRCKβ is still unclear (also see "Discussion" of the manuscript). To avoid potential confusion with the enzymatic activity of MRCKβ, we decided not to use the term "auto-inhibited conformation", instead we are now using the "closed conformation" in the revised manuscript. We also agree with the reviewer that more work will be required to understand the closed conformation of MRCKβ. But such study will be another major undertaking, and is probably beyond the scope of the current manuscript.
We have asked a native English speaker to help us editing the revised manuscript.
Reviewer #2: Major points: -The quality of most immunofluorescence (IF) is poor (especially figure 2 and 4) to draw any major conclusions on general localization of proteins. In most of the images cells look morphologically very different and might represent the somewhat heterogeneous nature of COS-7 cells. Quantification of changes in localization upon treatments/different constructs should be done from tens of cells (like for example using free Image J software and Pearson's correlation co-efficient).
We thank the reviewer for pointing this out. We consider ourselves as novices in the area of cell biology, and our poor choices of IF images reflect our lack of experience in the area. In the revised manuscript, we have improved the quality of IF images and used better quality images. The co-localizations of ZO-1 and MRCKβ at the leading edges of migrating cells are better presented (see revised Figure 2 and Figure 4) . As suggested by this reviewer and the reviewer #3, we requantified localizations of ZO-1 and MRCKβ. In this quantification, we adopted the method suggested by the reviewer #3 by measuring the ratio of cortical/cytoplasmic average fluorescence intensities ( Figure 2D and Figure 4E ), and the quantification was done from tens of cells (n≥17) for each experiment with the Student's t-test as the statistic method.
-The paper would benefit if the main findings (regarding localization and migration) could be reproduced also in a human cancer cell line. As suggested, we evaluated the leading edge co-localizations of ZO-1 and MRCKβ in two human cancer cell lines (PC/HK1 nasopharynx cancer cells and A549 lung cancer cells), and found that ZO-1 and MRCKβ are also co-localized at the leading edges of migrating cancer cells (Supplementary figure 2 of the revised manuscript). Figure 1E2 and 4D there is no ZO-1 blot shown). As suggested, we have included the ZO-1 blots of co-IP experiments in Figure 1E2 and Figure 4D .
-In all of the co-IPs it is necessary to show blots for both of the proteins (

Minor points: -Figure 1C2. Why is there growth of the yeast in both the control and the ZU5 expressing yeast with 940-1092 construct?
The results shown in Figure 1C2 were the experimental data we obtained. The weak growth of the 940-1092 construct in the control is likely due to some self-activation of the fragment in the Y2H assay. But the growth of the yeast on the right panel (containing ZU5 expressions) is obviously better than the left panel (the control) ( Figure 1C2 ). We also used pull-down assays to further confirm the binding between the 940-1092 fragment of MRCKβ and ZO-1 ZU5 ( Figure 1D1) . We have added a sentence to explain the slow growth of the 940-1092 construct in the Figure 1 legend.
-Since ZO-1 is an actin-binding protein and Cdc42-dependent MRCK activation is shown to reorganize the cytoskeleton (Leung 1998), actin staining in IF would be relevant/interesting.
We have performed actin staining in Supplementary figure 1A to identify the leading edges of migrating cells. The data showed that actin filaments are enriched at the leading edges and co-localized with ZO-1 very well. The data also hint that the ZO-1/MRCKβ complex may regulate the reorganization of cytoskeletons at the leading edges of migrating cells -Are the cells wounded in fig 4D co-IP (right-hand panel) ? Yes, the cells were wounded in Figure 4D co-IP experiments (both the upper right-hand panel and the lower panels). We have added this information in the labels of Figure 4D . Figure 2B6 the knock-down of MRCKbeta does not influence leading edge localisation of ZO-1. However, in the image this is not the case.
-In the text the authors say that in
We apologize again for the poor quality of image picked in the original manuscript. The replaced image for Figure 2B6 of the revised manuscript clearly shows that the knock-down of MRCKβ does not influence the leading edge localization of ZO-1.
We re-processed the images of Figure 2B6 shown in the original manuscript (see Figure I in the "Referee's only Supplementary Information"), as we do not want to be biased in presenting our experimental data. It can be observed that, in the MRCKβ knock-down cell, ZO-1is also localized at the leading edge.
-Is proliferation altered in any KD conditions which could affect cell migration e.g. in fig 7? As suggested, we checked the proliferation profiles of COS-7 cells in the wound-healing assays shown in Figure 7 , and found that proliferations of the cells under all conditions have no significant differences. We have included this data as Supplementary figure 11 in the revised manuscript.
-In Figure 7 it seems that in D and G also non-GFP cells are actively migrating into the wound even though one would assume that the rescue-construct would support migration only in the transfected cells. Why is this?
We think that two reasons might have contributed to the observation raised by the reviewer. First, our transfection method routinely achieved >80% transfection efficiencies, but could not reach 100% efficiency. Thus, the small amount of untransfected cells (i.e. containing neither the knockdown shRNA nor the rescue constructs) could still migrate after wounding. Secondly, a small population of transfected cells has faint fluorescence signals due to low levels of protein expression. These cells are not obvious in the figure due to the brightness of the images. When the brightness of the images is increased, we can have a better view of those cells with faint fluorescence signals. However, this would lead to image blurring of the cells with stronger GFP signals due to signal overflow. We had to choose a proper brightness of the images to best present our results.
-Phorbol esters are shown to bind MRCKa/b (Choi et al. 2008) . Could they by-pass the requirement for active Cdc42?
As suggested, we tested the effect of phorbol esters on possible release of the MRCKβ closed conformation. We find that TPA (12-O-tetradecanoylphorbol-13 -acetate, a commonly used phorbol ester) did not allow ZO-1 to by-pass Cdc42 to bind to MRCKβ (Supplementary figure 10B) . We have included this new data in Supplementary figure 10B of the revised manuscript.
-In figure 6D the authors state that active Cdc42 supports MRCKbeta recruitment to the leading edge, however in the image MRCKbeta is equally localizing to the lamellipodia in the transfected and the non-transfected cell shown in the bottom middle panel.
In Figure 6D , MRCKβ is almost equally localized to the lamellipodia in the Cdc42V12-transfected and the non-transfected cells. We think that the leading edge-localized MRCKβ is already activated and saturated by endogenous Cdc42. Thus, overexpressed Cdc42 cannot further enhance the leading edge localization of MRCKβ. In the Figure 6D legend, we added that "Overexpression of a constitutive active form of Cdc42 ("Cdc42V12") did not further enhance the leading edge localization of MRCKβ".
We have asked a native English speaker to help us editing the revised manuscript. We thank the reviewer for pointing out the logical gap in our manuscript. Following the reviewer's suggestion, we performed wound-healing assays by transfecting ZO-1 ΔZU5 or MRCKβ ΔZBD mutants (both are defective for the formation of the ZO-1/MRCKβ complex) after the knockdown of ZO-1 or MRCKβ, respectively. We observed that neither ZO-1 ΔZU5 nor MRCKβ ΔZBD could rescue the migration defects induced by the RNAi-mediated knock-downs of ZO-1 and MRCKβ, respectively. This result indicates that the direct interaction between ZO-1 and MRCKβ is indeed required for cell migrations mediated by the ZO-1/MRCKβ complex. We have included this data as Figure 7E and Figure 7I in We agree with the reviewer's comment that we cannot exclude other potential mechanisms/models (e.g. the ones put forward by the reviewer) based on our data. We have tuned down our conclusion by stating that "formation of the ZO-1/MRCKβ complex enriches kinase at the lamellae of migrating cells" in the revised manuscript.
Minor point:
The quantification in Figure 2A6 is not meaningful without knowing how a "cell periphery that contains a fluorescent signal" is defined. What is the threshold for this scoring mechanism? Ideally a relative measurement would be used, such as cortical/cytoplasmic.
We thank the reviewer for the suggestion. We re-quantified localizations of ZO-1 and MRCKβ in both Fig. 2 and Fig. 4 . In the quantifications, we adopted the method suggested by the reviewer by measuring the ratio of cortical/cytoplasmic average fluorescence intensities, and the quantifications were done from dozens of cells for each experiment (see Figure 2D and Figure 4E of the revised manuscript).
Additional Correspondence 14 December 2010
Many thanks for submitting the revised version of your manuscript EMBOJ-2010-75967R to the EMBO Journal. It has now been seen again by all three referees, whose comments are enclosed below. As you will see, all three referees find the manuscript to be substantially improved and are now fully supportive of publication. I am therefore pleased to be able to tell you that we will be able to accept your manuscript for publication here at the EMBO Journal. However, referee 3 does have one remaining minor concern that needs to be addressed by a slight modification of the text, as he/she outlines.
I do also have a number of minor issues from the editorial side that I would ask you to deal with before acceptance:
Firstly, in your abstract and in the final paragraph of your introduction, the impression is given that you do have structural data on the MRCKbeta/ZO-1 interaction. While both we and the referees are now satisfied that your structural analysis with GRIN1LA does provide insight into the MRCKbeta/ZO-1 interaction, it is important to be clear throughout what you have actually shown. Can I therefore ask you to change the following sentences to better reflect the content of the manuscript: Abstract: "Structural studies reveal that the binding of a beta-hairpin from MRCKbeta converts ZO-1 ZU5 into a complete ZU5 fold." Introdution: "The biochemical and structural basis of the ZO-1 ZU5 domain-mediated MRCKbeta interaction is characterised in detail." Please let me know if you need any help in reformulating these sentences.
